Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JNJ-73763989 + nucleos(t)ide analog + pegylated interferon alfa-2a
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Small Molecules, Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Recombinant Proteins and Enzymes, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Subcutaneous, Oral
01
Overview
This is a combination therapy for chronic hepatitis B, consisting of JNJ-73763989 (also known as JNJ-3989 or ARO-HBV, a liver-targeted small interfering RNA therapeutic that silences HBV transcripts), a nucleos(t)ide analog (oral antiviral that suppresses HBV replication), and pegylated interferon alfa-2a (an immunomodulatory agent that stimulates the host immune response to HBV)[1][3][4][5][9]. JNJ-73763989 contains two N-acetylgalactosamine-conjugated siRNAs targeting HBV RNAs, leading to reduction of all HBV proteins in hepatocytes. Nucleos(t)ide analogs inhibit HBV DNA polymerase and thus suppress viral replication. Pegylated interferon alfa-2a is an engineered form of interferon that activates antiviral and immune pathways via the JAK-STAT signaling cascade. The combination is designed to induce functional cure or deep viral suppression in chronic hepatitis B patients[3][5].
- Brand names
- Pegasys
- Other names
- peginterferon alfa-2apegylated interferon alfa-2anucleos(t)ide analog
02
Targets
HBV Pol (Hepatitis B virus polymerase)IFNAR (Immune system modulation via type I interferon receptor)
Beyond the preview
Go deeper on JNJ-73763989 + nucleos(t)ide analog + pegylated interferon alfa-2a.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JNJ-73763989 + nucleos(t)ide analog + pegylated interferon alfa-2a.